GAMMA Investing LLC Purchases 1,004 Shares of Exelixis, Inc. (NASDAQ:EXEL)

GAMMA Investing LLC boosted its position in Exelixis, Inc. (NASDAQ:EXEL) by 50.0% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,010 shares of the biotechnology company’s stock after purchasing an additional 1,004 shares during the quarter. GAMMA Investing LLC’s holdings in Exelixis were worth $78,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in EXEL. Goldman Sachs Group Inc. boosted its stake in shares of Exelixis by 0.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,048,809 shares of the biotechnology company’s stock valued at $25,161,000 after buying an additional 5,833 shares during the period. Wellington Management Group LLP lifted its position in shares of Exelixis by 25.1% during the 4th quarter. Wellington Management Group LLP now owns 129,935 shares of the biotechnology company’s stock valued at $3,117,000 after acquiring an additional 26,049 shares during the period. Fisher Asset Management LLC grew its holdings in shares of Exelixis by 232.6% during the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 728 shares in the last quarter. Nomura Holdings Inc. increased its position in shares of Exelixis by 234.4% in the fourth quarter. Nomura Holdings Inc. now owns 194,968 shares of the biotechnology company’s stock worth $4,677,000 after purchasing an additional 136,668 shares during the period. Finally, Los Angeles Capital Management LLC raised its stake in Exelixis by 948.3% in the first quarter. Los Angeles Capital Management LLC now owns 2,454,277 shares of the biotechnology company’s stock valued at $58,240,000 after purchasing an additional 2,220,150 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Christopher J. Senner sold 125,000 shares of the business’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $27.19, for a total value of $3,398,750.00. Following the transaction, the chief financial officer now directly owns 721,680 shares of the company’s stock, valued at $19,622,479.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Exelixis news, CFO Christopher J. Senner sold 125,000 shares of the firm’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $27.19, for a total value of $3,398,750.00. Following the completion of the sale, the chief financial officer now directly owns 721,680 shares in the company, valued at approximately $19,622,479.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Dana Aftab sold 95,000 shares of the stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the transaction, the executive vice president now directly owns 520,990 shares in the company, valued at $13,024,750. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 327,858 shares of company stock worth $8,640,129. Company insiders own 2.85% of the company’s stock.

Exelixis Stock Performance

NASDAQ:EXEL opened at $28.50 on Wednesday. Exelixis, Inc. has a fifty-two week low of $18.64 and a fifty-two week high of $28.99. The company has a 50 day simple moving average of $26.29 and a two-hundred day simple moving average of $23.72. The company has a market capitalization of $8.64 billion, a PE ratio of 44.53, a P/E/G ratio of 0.54 and a beta of 0.54.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.44. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. The company had revenue of $637.18 million during the quarter, compared to analysts’ expectations of $468.21 million. Research analysts predict that Exelixis, Inc. will post 1.59 EPS for the current year.

Wall Street Analysts Forecast Growth

EXEL has been the topic of several recent analyst reports. Royal Bank of Canada raised their target price on shares of Exelixis from $27.00 to $30.00 and gave the company an “outperform” rating in a report on Friday, October 4th. UBS Group began coverage on Exelixis in a research report on Thursday, September 19th. They issued a “neutral” rating and a $30.00 target price on the stock. Bank of America raised their price target on shares of Exelixis from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday. JMP Securities reissued a “market outperform” rating and issued a $29.00 price objective on shares of Exelixis in a research note on Friday, October 11th. Finally, StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 13th. Five analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $28.43.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.